These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8273794)

  • 1. Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori.
    Borody TJ; Brandl S; Andrews P; Ferch N; Jankiewicz E; Hyland L
    Am J Gastroenterol; 1994 Jan; 89(1):33-8. PubMed ID: 8273794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
    Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
    Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
    Thijs JC; van Zwet AA; Moolenaar W; Wolfhagen MJ; ten Bokkel Huinink J
    Am J Gastroenterol; 1996 Jan; 91(1):93-7. PubMed ID: 8561152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin].
    Zala G; Schwery S; Giezendanner S; Flury R; Wüst J; Meyenberger C; Wirth HP
    Schweiz Med Wochenschr; 1996 Feb; 126(5):153-8. PubMed ID: 8685685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
    Graham DY; Belson G; Abudayyeh S; Osato MS; Dore MP; El-Zimaity HM
    Dig Liver Dis; 2004 Jun; 36(6):384-7. PubMed ID: 15248377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule.
    de Boer WA; van Etten RJ; Schneeberger PM; Tytgat GN
    Am J Gastroenterol; 2000 Mar; 95(3):641-5. PubMed ID: 10710051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
    Lerang F; Moum B; Haug JB; Tolås P; Breder O; Aubert E; Høie O; Søberg T; Flaaten B; Farup P; Berge T
    Am J Gastroenterol; 1997 Feb; 92(2):248-53. PubMed ID: 9040200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.
    Graham DY; Opekun AR; Belson G; El-Zimaity HM; Carlson MR
    Aliment Pharmacol Ther; 2005 Jan; 21(2):165-8. PubMed ID: 15679766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
    Kang JM; Kim N; Lee DH; Park YS; Kim YR; Kim JS; Jung HC; Song IS
    Helicobacter; 2007 Dec; 12(6):623-8. PubMed ID: 18001404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer.
    Tzivras M; Archimandritis A; Balatsos V; Delis V; Souyioultzis S; Skandalis N; Kanellopoulou E; Manika Z; Davaris P
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1185-9. PubMed ID: 9471024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study.
    Cremonini F; Di Caro S; Covino M; Armuzzi A; Gabrielli M; Santarelli L; Nista EC; Cammarota G; Gasbarrini G; Gasbarrini A
    Am J Gastroenterol; 2002 Nov; 97(11):2744-9. PubMed ID: 12425542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.
    Dore MP; Graham DY; Mele R; Marras L; Nieddu S; Manca A; Realdi G
    Am J Gastroenterol; 2002 Apr; 97(4):857-60. PubMed ID: 12003419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
    de Boer WA; Haeck PW; Otten MH; Mulder CJ
    Am J Gastroenterol; 1998 Jul; 93(7):1101-7. PubMed ID: 9672338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
    Lara LF; Cisneros G; Gurney M; Van Ness M; Jarjoura D; Moauro B; Polen A; Rutecki G; Whittier F
    Arch Intern Med; 2003 Sep; 163(17):2079-84. PubMed ID: 14504122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone.
    Nijevitch AA; Shcherbakov PL; Sataev VU; Khasanov RSh; Al Khashash R; Tuygunov MM
    Aliment Pharmacol Ther; 2005 Nov; 22(9):881-7. PubMed ID: 16225499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease].
    Labenz J; Gyenes E; Rühl GH; Börsch G
    Med Klin (Munich); 1993 May; 88(5):297-9. PubMed ID: 8326916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.